-

Rezilon™ Herbicide Receives EPA Approval

New herbicide provides better hay quality by controlling summer and winter annual broadleaf weeds and grasses

CARY, N.C.--(BUSINESS WIRE)--The Vegetation Management business within Bayer CropScience LP, announces the label for Rezilon Herbicide has received approval from the U.S. Environmental Protection Agency (EPA). The herbicide is federally registered for the control of summer and winter annual broadleaf weeds and grasses in pastures and hayfields, non-irrigation ditchbanks, fire breaks and any sites managed for hay.

Rezilon herbicide is a pre-emergence herbicide that provides consistent control of annual grass and broadleaf weeds in warm-season bermudagrass and Bahiagrass hay fields. It also helps protect desirable warm-season grasses while managing unwanted annual grasses in the same site, a quality that few herbicides can maintain.

For year-round control of broadleaf and annual grass weeds, Rezilon is applied in both late summer and late winter. Applications made in August, September or October will provide pre-emergence control of fall-emerging weeds, while applications made in January or February will provide pre-emergence control of spring-emerging weeds.

Rezilon herbicide includes indaziflam, an innovative active ingredient that works primarily to target broadleaf and annual grass weeds in established bermudagrass. With indaziflam, Rezilon gives growers the opportunity to use a new mode of action to achieve the effective weed control they desire on their hay production sites. By eliminating weeds, Rezilon also helps to increase fertilizer and water utilization in hay and forage production. In fact, when applied according to label directions, growers could see a higher-quality forage produced on their first harvest.

“We are pleased to see Rezilon herbicide receive federal approval from the EPA,” said Bayer Head of Vegetation Management Marketing, North America, Tiffany Fremder. “Rezilon will give hay growers the weed control they’ve been asking for, while also allowing them to improve quality on their hay production sites.”

Overall, the herbicide controls more than 60 broadleaf and annual grass weeds, including species that have developed herbicide resistance, such as ryegrass. Using Rezilon as directed also reduces the time and money hay growers would otherwise need to spend on additional herbicide applications.

Rezilon herbicide has long-lasting residual activity for extended control of weeds throughout the season. For best results, it should be applied well before weed emergence. Once applied, Rezilon can sit on the soil surface for some time with no degradation from sunlight while waiting on rainfall for activation.

On Tuesday, August 11, 2020, Bayer will host a panel of regional experts for a live online discussion about how Rezilon offers consistent, long-term weed control for increased hay production and quality. The live discussion will take place from 9 a.m. to 11:30 a.m. Central time. Join the webinar here.

First sales of Rezilon herbicide are anticipated in August 2020 following state registrations.

For more information on Rezilon herbicide, contact your local Bayer sales representative or visit: www.rezilon.com.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to benefit people by supporting efforts to overcome the major challenges presented by a growing and aging global population. At the same time, the Group aims to increase its earning power and create value through innovation and growth. Bayer is committed to the principles of sustainable development, and the Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2019, the Group employed around 104,000 people and had sales of 43.5 billion euros. Capital expenditures amounted to 2.9 billion euros, R&D expenses to 5.3 billion euros. For more information, go to www.bayer.com.

Forward-Looking Statements

This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

ALWAYS READ AND FOLLOW LABEL INSTRUCTIONS.

Bayer Environmental Science, a business unit of Bayer CropScience LP, 5000 CentreGreen Way, Suite 400, Cary, NC 27513. 1-800-331-2867. www.environmentalscience.bayer.us. Bayer, the Bayer Cross and Rezilon are trademarks of Bayer. Not all products are registered in all states. Always read and follow label instructions carefully. ©2020 Bayer CropScience LP.

Contacts

Bayer Media Hotline, 1-862-404-5118, or

Tiffany Fremder
Head of IVM Marketing, North America
Environmental Science, a Division of Bayer CropScience
Email: tiffany.fremder@bayer.com

Erica Ballmer
Rhea + Kaiser
Tel: (630) 955-2514
Email: eballmer@rkconnect.com

Bayer


Release Versions

Contacts

Bayer Media Hotline, 1-862-404-5118, or

Tiffany Fremder
Head of IVM Marketing, North America
Environmental Science, a Division of Bayer CropScience
Email: tiffany.fremder@bayer.com

Erica Ballmer
Rhea + Kaiser
Tel: (630) 955-2514
Email: eballmer@rkconnect.com

More News From Bayer

Bayer® Aspirin Partners with Celebrity Chef Jeff Mauro for Immersive Dark Dining Experience This American Heart Month

WHIPPANY, N.J.--(BUSINESS WIRE)--This American Heart Month, Bayer® Aspirin continues its mission to help people uncover the heart health risk factors they may not see with the launch of the Heart to Heart Bistro presented by Bayer® Aspirin. Created in partnership with Celebrity Chef, Jeff Mauro, the immersive dark dining experience invites Americans to confront one of the most dangerous and often overlooked barriers to heart health – denial – by bringing the unseen risk factors of cardiovascula...

Bayer’s Asundexian Demonstrated a Substantial 26% Reduction in Stroke After a Non-Cardioembolic Ischemic Stroke or High-Risk Transient Ischemic Attack, With No Increase in ISTH Major Bleeding Versus Placebo

NEW ORLEANS--(BUSINESS WIRE)--Bayer today presented the results from the global, pivotal Phase III OCEANIC-STROKE study evaluating the use of its investigational, once-daily, oral, Factor XIa inhibitor asundexian (50mg) compared to placebo, both in combination with antiplatelet therapy. Asundexian significantly reduced ischemic stroke by 26% (csHR 0.74; 95% CI 0.65–0.84; p<.0001), in patients after a non-cardioembolic ischemic stroke or high-risk transient ischemic attack, with no increase i...

Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Teams Up with Former Professional Quarterback Tony Romo on ‘Highlights REAL’ Campaign...
Back to Newsroom